Recombinant-Human-Hyaluronidase-PH20-in-Biologics-and-Immunoglobulin-Therapy

Amy E. Clarke, DNP, RN, IgCN®Chief Clinical OfficerImmunoglobulin National SocietyCalabasas, CaliforniaLuba Sobolevsky, PharmD, IgCP®President and CEOImmunoglobulin National SocietyCalabasas, CaliforniaDavid KangDirectorHalozyme Therapeutics, IncSan Diego, CaliforniaMarie PrintzExecutive DirectorHalozyme Therapeutics, IncSan Diego, CaliforniaSubcutaneous (SC) delivery has become a preferred route across many therapeutic areas because it reduces reliance on infusion suites, shifts care in